These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2119792)

  • 1. Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma.
    Gottlieb DJ; Prentice HG; Mehta AB; Galazka AR; Heslop HE; Hoffbrand AV; Brenner MK
    Br J Haematol; 1990 Aug; 75(4):499-505. PubMed ID: 2119792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation.
    Heslop HE; Duncombe AS; Reittie JE; Bello-Fernandez C; Gottlieb DJ; Prentice HG; Mehta AB; Hoffbrand AV; Brenner MK
    Br J Haematol; 1991 Feb; 77(2):237-44. PubMed ID: 2004026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.
    Gottlieb DJ; Prentice HG; Heslop HE; Bello-Fernandez C; Bianchi AC; Galazka AR; Brenner MK
    Blood; 1989 Nov; 74(7):2335-42. PubMed ID: 2804369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactive effects of alpha-interferon A/D and interleukin 2 on murine lymphokine-activated killer activity: analysis at the effector and precursor level.
    Chikkala NF; Lewis I; Ulchaker J; Stanley J; Tubbs R; Finke JH
    Cancer Res; 1990 Feb; 50(4):1176-82. PubMed ID: 2297766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies.
    Higuchi CM; Thompson JA; Petersen FB; Buckner CD; Fefer A
    Blood; 1991 Jun; 77(12):2561-8. PubMed ID: 2043762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine-induced enhancement of the susceptibility of hairy cell leukaemia lymphocytes to natural killer cell lysis.
    Cordingley FT; Hoffbrand AV; Brenner MK
    Br J Haematol; 1988 Sep; 70(1):37-41. PubMed ID: 3140887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
    Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
    Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors.
    Guarini A; Sanavio F; Novarino A; Gillio Tos A; Aglietta M; Foa R
    Br J Haematol; 1991 Nov; 79(3):451-6. PubMed ID: 1751372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease.
    Gottlieb DJ; Brenner MK; Heslop HE; Bianchi AC; Bello-Fernandez C; Mehta AB; Newland AC; Galazka AR; Scott EM; Hoffbrand AV
    Br J Cancer; 1989 Oct; 60(4):610-5. PubMed ID: 2803933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous and interleukin 2 induced secretion of tumour necrosis factor and gamma interferon following autologous marrow transplantation or chemotherapy.
    Heslop HE; Gottlieb DJ; Reittie JE; Bello-Fernandez C; Meager A; Prentice HG; Brenner MK
    Br J Haematol; 1989 Jun; 72(2):122-6. PubMed ID: 2503022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer cell function of lymphocytes from regional lymph nodes in patients with gastric carcinoma.
    Arinaga S; Karimine N; Nanbara S; Inoue H; Nakashima H; Ueo H; Akiyoshi T
    J Surg Oncol; 1995 Jan; 58(1):44-9. PubMed ID: 7823572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.
    Rodolfo M; Salvi C; Bassi C; Rovetta G; Melani C; Colombo MP; Parmiani G
    Nat Immun Cell Growth Regul; 1991; 10(6):308-19. PubMed ID: 1787836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of allogeneic and autologous melanoma cells by IL-7-induced lymphokine-activated killer cells.
    Böhm M; Möller P; Kalbfleisch U; Worm M; Czarnetzki BM; Schadendorf D
    Br J Cancer; 1994 Jul; 70(1):54-9. PubMed ID: 8018541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-mediated toxicity of interleukin-2-activated lymphocytes against autologous and allogeneic human myeloma cells.
    Shimazaki C; Atzpodien J; Wisniewski D; Gulati SC; Kolitz JE; Fried J; Clarkson BD
    Acta Haematol; 1988; 80(4):203-9. PubMed ID: 3146198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.